Efficacy and safety of enzalutamide plus androgen deprivation therapy vs placebo plus androgen deprivation therapy in men with metastatic hormone-sensitive prostate cancer: the ongoing ARCHES trial
Publication
, Journal Article
Stenzl, A; Krivoshik, A; Baron, B; Hirmand, M; Armstrong, A
Published in: Annals of Oncology
October 1, 2016
Duke Scholars
Published In
Annals of Oncology
DOI
EISSN
1569-8041
ISSN
0923-7534
Publication Date
October 1, 2016
Volume
27
Start / End Page
vi262
Related Subject Headings
- Oncology & Carcinogenesis
- 3211 Oncology and carcinogenesis
- 3202 Clinical sciences
- 1112 Oncology and Carcinogenesis
Citation
APA
Chicago
ICMJE
MLA
NLM
Stenzl, A., Krivoshik, A., Baron, B., Hirmand, M., & Armstrong, A. (2016). Efficacy and safety of enzalutamide plus androgen deprivation therapy vs placebo plus androgen deprivation therapy in men with metastatic hormone-sensitive prostate cancer: the ongoing ARCHES trial. Annals of Oncology, 27, vi262. https://doi.org/10.1093/annonc/mdw372.51
Stenzl, A., A. Krivoshik, B. Baron, M. Hirmand, and A. Armstrong. “Efficacy and safety of enzalutamide plus androgen deprivation therapy vs placebo plus androgen deprivation therapy in men with metastatic hormone-sensitive prostate cancer: the ongoing ARCHES trial.” Annals of Oncology 27 (October 1, 2016): vi262. https://doi.org/10.1093/annonc/mdw372.51.
Stenzl A, Krivoshik A, Baron B, Hirmand M, Armstrong A. Efficacy and safety of enzalutamide plus androgen deprivation therapy vs placebo plus androgen deprivation therapy in men with metastatic hormone-sensitive prostate cancer: the ongoing ARCHES trial. Annals of Oncology. 2016 Oct 1;27:vi262.
Stenzl, A., et al. “Efficacy and safety of enzalutamide plus androgen deprivation therapy vs placebo plus androgen deprivation therapy in men with metastatic hormone-sensitive prostate cancer: the ongoing ARCHES trial.” Annals of Oncology, vol. 27, Oct. 2016, p. vi262. Scopus, doi:10.1093/annonc/mdw372.51.
Stenzl A, Krivoshik A, Baron B, Hirmand M, Armstrong A. Efficacy and safety of enzalutamide plus androgen deprivation therapy vs placebo plus androgen deprivation therapy in men with metastatic hormone-sensitive prostate cancer: the ongoing ARCHES trial. Annals of Oncology. 2016 Oct 1;27:vi262.
Published In
Annals of Oncology
DOI
EISSN
1569-8041
ISSN
0923-7534
Publication Date
October 1, 2016
Volume
27
Start / End Page
vi262
Related Subject Headings
- Oncology & Carcinogenesis
- 3211 Oncology and carcinogenesis
- 3202 Clinical sciences
- 1112 Oncology and Carcinogenesis